New Study Supporting The Pivotal Role Of Tumor Grade In Chemotherapy Prescription At The 32nd Annual San Antonio Breast Cancer Symposium
Main Category: Breast CancerAlso Included In: Cancer / Oncology; Women's Health / Gynecology
Article Date: 26 Dec 2009 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Ipsogen SA (Alternext: ALIPS) today announced that a new study confirming the pivotal role of tumor grade in chemotherapy prescription has been presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2009.
The study was conducted at Institut Paoli Calmettes (IPC) Cancer Centre, Marseille, France. Using the centre database and a classification tree method, it retrospectively examined the tumor and patient characteristics driving prescription of adjuvant chemotherapy for 5854 early stage node negative (M-/N-), invasive breast cancer (IBC) patients treated between 1999 and 2005.
The study results indicate that tumor grade is the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size. Hierarchy of factors driving chemotherapy decision is remarkably stable over time, despite the progressive availability of new pathologic indicators over time.
"These new findings further support the value of Genomic Grade -a tool to refine tumor grading by resolving intermediate histologic grade 2 tumors in which indication of chemotherapy is a clinical challenge - for treatment decision making. Integrated in currently validated treatment algorithms using tumor grade, the Genomic Grade could contribute to a more individualized chemotherapy strategy in Invasive Breast Cancer" comments Hélène Peyro-Saint-Paul, Ipsogen Chief Medical Officer.
The study was presented at Poster Session 2, Friday, Dec 11, 2009, abstract # 2089:
Title: Real-life implementation of treatment guidelines for adjuvant chemotherapy in invasive breast cancer: retrospective analysis of a large single centre 10-year database.
Jean-Marie Boher, Jean-Marc Extra, Jacques Camerlo, Carole Tarpin, Emmanuelle Charaffe-Jauffret, Eric Lambaudie, Agnes Tallet, Hélène Peyro-Saint-Paul, Patrice Viens
Source
Ipsogen
Visit our breast cancer section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/174707.php>
APA
http://www.medicalnewstoday.com/releases/174707.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




